story of the week
First-Line Nivolumab + Ipilimumab Combined With Two Cycles of Chemotherapy in NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-Line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial
Lancet Oncol 2021 Jan 18;[EPub Ahead of Print], L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, E Richardet, J Bennouna, E Felip, O Juan-Vidal, A Alexandru, H Sakai, A Lingua, P Salman, PJ Souquet, P De Marchi, C Martin, M Pérol, A Scherpereel, S Lu, T John, DP Carbone, S Meadows-Shropshire, S Agrawal, A Oukessou, J Yan, M ReckFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.